Article

Belkin Laser changes corporate name to Belkin Vision

The company, formerly called BELKIN Laser, announced Thursday that it will begin operating under the new name BELKIN Vision.

BELKIN Laser announced Thursday it has changed its corporate name to BELKIN Vision.

BELKIN Laser announced Thursday it has changed its corporate name to BELKIN Vision.


BELKIN Vision, an Israeli-based medical device company, announced Thursday that the company will begin operating under the new name BELKIN Vision.

This corporate name change was determined as part of a strategic decision to better reflect the company's future plans, according to CEO/co-founder Daria Lemann Blumenthal.

Established in 2013, BELKIN was launched from with the goal of providing accessible glaucoma laser treatment to patients with the same ease as prescribing eye drops.

The company is working to develop technology centered around a transscleral approach to provide an automated laser treatment completed in one second.

The simplicity of the idea would allow the laser treatment to be administered by all eye care providers making first-line glaucoma treatment available for every patient worldwide, according to the company's website.

"We always imagined (starting the company) would transport us to the stage we're at today. Now, on the cusp of commercialization, we anticipate a multitude of exciting future applications and wanted to ensure that our company name aligned with that vision," Lemann Blumentha said, in a statement.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.